Shares of Insmed Inc. dropped 52.5 percent Tuesday after data from a two-year rat carcinogenicity study prompted the FDA to slap a clinical hold on a pair of nascent Phase III trials with lung infection drug Arikace (liposomal amikacin for inhalation). Read More
Science and the FDA are paving a way for personalized medicine, but whether there's a will to turn that way into a thriving thoroughfare remains to be seen. Read More
One fact of life in the genomics era is that in some cases, what was once one cancer – breast, colon, lung – is now a bewildering range of diseases whose anatomical site may just be beside the point in terms of how best to treat them. The situation bears some resemblance to Leo Tolstoy's famous assertion in Anna Karenina that "every unhappy family is unhappy in its own way." Read More
LONDON – The UK's golden triangle of biotech centered on London, Cambridge and Oxford is transitioning into a supercluster, as it leaves the rest of the country behind in terms of its percentage share of fundraising. Read More
Jennerex Inc., of San Francisco, reported positive results from a proof-of-concept trial of JX-594, an oncolytic virus, for metastatic melanoma. Read More
Bioniche Life Sciences Inc., of Belleville, Ontario, will not acquire the assets of Plasvacc Holdings Ltd., of Australia, as it had previously planned. No agreement was reached, and discussions were terminated. Read More
